BRAF Fusion

CI-VAR-00001171Explore in graph →CIViC 286

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma2
PAPSS1::BRAF Fusion	Trametinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID726 BRAF-fusion in "pan-negative" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This… (full text at CIViC) PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC	civic
PAPSS1::BRAF Fusion	Vemurafenib	Predictive	D	Supports Resistance	3	accepted	EID725 BRAF-fusion in "pan-negative" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib. PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.